Topic Archives: GlaxoSmithKline (GSK)

Everyone seems to love a “micro cap” these days, so the latest teaser pitch from Dylan Jovine over at Behind the Markets for his “upgrade” newsletter caught my eye — it’s called Breakthrough Wealth ($997/yr, 30-day refund policy), and he’s pitching a service that he says will be shooting for 1,000% gains in small companies. […]

When I last took a look at what was happening in the treatment of migraines, I took careful pains to elucidate the differences between migraines and a plain old bad headache – the fact that migraines affect only one side of the head, and a detailed disquisition on the symptoms that many migraineurs (that’s the […]

Glenn Newberry in an earlier post today was asking whether Benlysta from GlaxoSmithKline (GSK), being trialled for lupus nephritis, poses any threat to Aurinia (AUPH). Benlysta is a monoclonal antibody that binds to and inhibits BAFF (B-cell activating factor). A company called Anthera (ANTH) is trialling blisibimod, an oral agent that does the same thing. […]

[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]

[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He choses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Enjoy!] In his smoky baritone, singer Stuart Staples of British midlands musical act Tindersticks is bemoaning how he suspects the woman he […]

“I firmly believe that if the whole materia medica could be sunk to the bottom of the sea, it would be all the better for mankind and all the worse for the fishes.”  — Oliver Wendell Holmes, M. D., Professor of Medicine , Harvard “With all his conscience and one eye askew, So false he […]

[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He chooses his own topics, and his words and opinions are his own.] Careful analysis of Ebola sequences in infected Africans confirms this: the entire present Ebola outbreak emerged as a consequence of one boy in Meliandoua, in eastern Guinea, eating a […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Today we’re sharing another piece from our medical contributor, “Doc Gumshoe” — we have added the stock tickers to the companies he mentions for your researching convenience, but this survey of the state of cancer research — which will hopefully be good background help to folks trying to understand the basic science behind pitches for […]


  • Avatar

    FWIW: Here's background on FULC's only Phase 1-2 trial in progress: "Fulcrum acquired rights to losmapimod from GlaxoSmi...

  • Avatar

    $GILD $GSK #HIV - Barrons just published an article on this subject, quoting a Piper Jaffray's analyst who mildly refute...

  • Avatar

    Was this what the Dr. was forseeing? Introducing PfizerKline: Analyst Makes New Case for Merger of GlaxoSmithKline (GSK...

  • omcdac1

    Team, Anyone have this company in watch-list, Glenn ? Pipeline is very impressive ...

  • Avatar

    This company Agenus (AGEN) could be a target of GlaxoSmithKline (GSK) after this news today with this phase 3 shingles v...

  • Avatar

    Clovis Oncology ($CLVS) is teaming up with GlaxoSmithKline ($GSK) in a new non-small cell lung cancer trial targeting EG...

  • Travis Johnson, Stock Gumshoe

    True, there are always expensive companies, but that's 20X estimated earnings for 2017, 30 months into the future. BMY ...

  • Avatar

    RE: GILD First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy i...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info